Urologic Oncology
Presurgy S.L. is active in non-muscle invasive bladder cancer, with research centered on adjuvant treatment strategies for high-grade disease in the bladder.
- Bladder cancer
- Non-muscle invasive disease
- High-grade urothelial carcinoma
The sponsor’s clinical interest in this area reflects a focus on treatment options used after initial tumor management to address recurrence risk and disease control.
Intravesical Therapy
The funded research includes intravesical treatment approaches for bladder cancer, comparing a supportive mitomycin C strategy with standard immunotherapy.
- Mitomycin C
- Intravesical instillation
- Immunotherapy
This therapeutic area is relevant to local drug delivery in the bladder and to established bladder-preserving treatment pathways.
Electric Current–Assisted Drug Delivery
Presurgy S.L. supports research into electromotive drug administration, using electric current to enhance delivery of mitomycin C within the bladder.
- Electromotive administration
- Electric current–assisted delivery
- Supportive chemotherapy
This area links device-enabled drug delivery with bladder-directed oncology care.
Maintenance Treatment in Bladder Cancer
The sponsor’s trial activity also addresses maintenance therapy in high-grade non-muscle invasive bladder cancer, with attention to sustained disease management over time.
- Maintenance instillation
- Recurrence prevention
- Adjuvant treatment
These interests place emphasis on prolonged bladder-sparing treatment approaches in a cancer setting where local control is clinically important.
